Abstract
Concern has been raised about an increased risk of lymphoma and skin cancers in patients with rheumatoid arthritis due to administration of anti-TNF-α drugs. Meta-analysis of observational data from registries as well as from randomized controlled trials has failed to show a significant increase in the risk of lymphoma when the sample size has been sufficiently large; skin cancer risk may represent a valid concern. Issues relating to interpretation of these data are discussed.
This is a preview of subscription content, log in via an institution to check access.
References
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltslius N, Coster L, Geborek P, Jacobsen LT, Lindblad S, Rantapaa-Dahlqvist S, Saxne T, Klareskog L (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies. Does the risk change with the time since start of treatment? Arthr Rheum 60:3180–3189
Beacklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Irinel AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthr Rheum 54:692–701
Clark DA (2012) The end of evidence-based medicine? Inflammopharmacology 20:187–193
Drug Safety Committee (2012) Drug Safety Quarterly 4(2):1–4
Horton SC, Nam JL, Buch MH (2012) Safety of biologics in rheumatoid arthritis. Int J Clin Rheumatol 7:425–251 (Medscape CME, http://www.medscape.org/viewarticle/768769)
Kahneman D (2011) Thinking fast and slow. Doubleday, Canada
Lopez-Olivio MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fultom S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biological therapy. JAMA 308:898–908
Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbacj D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P (2010) Lymphoma in patients treated with anti-TNF: results of the 3 year prospective French RATIO registry. Ann Rheum Dis 69:400–408
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven A, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904
Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzanai C, Gorla R, Marchesoni A, Favalli EG, Montecucco C (2010) Tumor necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175–180
Schwartz RS (1974) Immunosuppressive chemotherapy and malignancy. Transpl Proc 6(Suppl 1):45–48
Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook G, Schneeweiss S (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthr Rheum 54:2757–2764
Solomon DH, Mercer E, Kavanaugh A (2012) Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis. Arthr Rheum 64:21–32
Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthr Rheum 56:2886–2895
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clark, D.A. Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?. Inflammopharmacol 21, 125–127 (2013). https://doi.org/10.1007/s10787-012-0158-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-012-0158-0